In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...
1d
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...
In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...
The Biden administration proposed expanding coverage of weight loss medication to Medicaid and Medicare recipients. RFK Jr.
Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...
Per the results of the study, patients taking Zepbound experienced a loss of 20% of their body weight on average. By ...
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback